Pipeline
EpiQure™
We have created a platform for high-throughput, low-cost elucidation of action and toxicology of epigenetic drugs. Our multiplexed workflow enables comprehensive, combinatorial, quantitative, epigenetic profiling on a large number of samples. Its impact lies in reducing attrition and accelerating time-to-market for epigenetic cancer drugs (and drugs in general). EpiQure is quantitative technology for epigenetic drug efficacy and toxicity screening in real-life pilots, to match pharmaceutical industry requirements and address the need to lower R&D costs through reduced attrition. The technology framework allows high-throughput, low-cost elucidation of shortand long-term action and toxicology of drugs. The competitive advantage of our technology lies in delivering quantitative information on a high number of biomarkers at a 50-100 fold price decrease.
EpiFinder™
Enables and accelerates large-scale biomarker discovery for disease diagnosis, prognosis and selection of targeted therapies required for personalised medicine. Epigenica’s genome-wide epigenetic profiling technology, will enable and accelerate large-scale epigenetic biomarker discovery.
EpIVD™
Speeds up and lowers the costs of epigenetic diagnostics, especially relevant to the diagnosis of cancer and disease conditions in general, and further informing the choice and/or dose of treatment in personalised medicine approaches.
